Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Other Operating Expenses (2016 - 2017)

IGC Pharma has reported Other Operating Expenses over the past 4 years, most recently at -$757260.0 for Q1 2017.

  • Quarterly Other Operating Expenses rose 32.34% to -$757260.0 in Q1 2017 from the year-ago period, while the trailing twelve-month figure was -$757260.0 through Dec 2017, up 66.03% year-over-year, with the annual reading at -$1.9 million for FY2017, 33.51% up from the prior year.
  • Other Operating Expenses was -$757260.0 for Q1 2017 at IGC Pharma, down from -$111960.0 in the prior quarter.
  • Over five years, Other Operating Expenses peaked at -$111960.0 in Q4 2016 and troughed at -$1.2 million in Q2 2014.
  • The 4-year median for Other Operating Expenses is -$685867.0 (2016), against an average of -$687939.0.
  • The largest YoY upside for Other Operating Expenses was 88.75% in 2016 against a maximum downside of 97.69% in 2016.
  • A 4-year view of Other Operating Expenses shows it stood at -$593845.0 in 2014, then tumbled by 67.64% to -$995502.0 in 2015, then skyrocketed by 88.75% to -$111960.0 in 2016, then tumbled by 576.37% to -$757260.0 in 2017.
  • Per Business Quant, the three most recent readings for IGC's Other Operating Expenses are -$757260.0 (Q1 2017), -$111960.0 (Q4 2016), and -$614474.0 (Q3 2016).